The patient: Emerging clinical applications of intravenous immunoglobulin

Pharmacotherapy

Volumn 25, Issue 11 II, 2005, Pages

  Harvey III, R Donald ^a,b  

^a Georgia Cancer Center for Excellence ^*  (United States)

^b BCOP   (United States)

Author keywords

Antibodies; Human immunodeficiency virus; IGIV; Immunomodulation; Intravenous immunoglobulin; Renal transplantation

Indexed keywords

IMMUNOGLOBULIN;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MARKETING; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNOMODULATION; KIDNEY TRANSPLANTATION; NEUROLOGIC DISEASE; PASSIVE IMMUNIZATION; SKIN DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS;

EID: 27644533904     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11part2.85S     Document Type: Conference Paper

References (48)

1. Medeiros D, Buchanan GR. Current controversies in the management of idiopathic thrombocytopenic purpura in childhood. Pediatr Clin North Am 1996;43:757-72.
2. Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999;105:871-5.
3. Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol 2003;10:165-9.
4. Gelfand EW. Antibody-directed therapy: past, present, and future. J Allergy Clin Immunol 2001;108(suppl 4):S111-16.
5. Strand V. Proposed mechanism for the efficacy of intravenous immunoglobulin treatment. In: Lee ML, Strand V, eds. Intravenous immunoglobulins in clinical practice. New York: Marcel Dekker, 1997:23-36.
6. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-97.
7. Crow AR, Lazarus AH. Role of Fcγ receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25(suppl 1):S14-18.
8. Medical Research Council Working Party on Hypogammaglobulinaemia. Hypogammaglobulinaemia in the United Kingdom. Special report series 310. London: Her Majesty's Stationary Office, 1974.
9. Kazatchkine MD, Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
10. Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Biodrugs 2002;15:47-55.
11. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the control of complement action. Immunol Res 2000;22:137-46.
12. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002;59(12 suppl 6):S13-21.
13. Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003;24(suppl 4):S256-9.
14. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IGIV mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
15. Kaveri SV, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 1994;57(suppl):6-8.
16. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104(suppl 1):3-9.
17. French LE, Tschopp J. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition. Schweiz Med Wochenschr 2000;130:1656-61.
18. Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology classification and management. Best Pract Res Clin Haematol 2001;14:401-36.
19. Callen JP. Dermatomyositis. Lancet 2000;355:53-7.
20. Nobile-Orazio E, Terenghi F, Carpo M, Bersano A. Treatment of multifocal motor neuropathy. Neurol Sci 2003;24(suppl 4):S251-5.
21. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2003;2:CD002277.
22. Maddison P, Newsom-Davis J. Treatment for Lambert-Easton myasthenic syndrome. Cochrane Database Syst Rev 2003;2:CD003279.
23. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003;60(8 suppl 3):S2-7.
24. Ropper AH. Current treatment for CIDP. Neurology 2003;60(8 suppl 3):S16-22.
25. Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;2:CD001797.
26. Sacher RA. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 2001;108(suppl 4):S139-46.
27. Consensus Working Group. Present and future uses of intravenous immune globulin (IGIV): a Canadian multidisciplinary consensus-building initiative, May 24, 1997. Toronto: Maclean Hunter Healthcare/Santé, 1997.
28. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003;3:653-64.
29. Jordan SC, Tyan D, Stablein D, et al. Evaluation of IGIV as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-62.
30. Hughes R, Raphael J, Swan A, Doom P. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2004;1:CD002063.
31. Sorensen PS. The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 2003;206:123-30.
32. Sorensen PS. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Neurol Sci 2003;24(suppl 4):S227-30.
33. Rutter A, Luger TA. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr Opin Investig Drugs 2002;3:713-19.
34. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9.
35. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003;112:1430-6.
36. Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003;17:641-5.
37. Mutasim DF. Autoimmune bullous dermatoses in the elderly: diagnosis and management. Drugs Aging 2003;20:663-81.
38. Ratko TA, Burnett DA, Foulke GE, et al. Consensus statement: recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273:1865-70.
39. Abernathy RS, Strem EL, Good RA. Chronic asthma in childhood: double-blind controlled study of treatment with gamma-globulin. Pediatrics 1958;61:980-92.
40. Smith TF, Muldoon MF, Bain RP, et al. Clinical results of a prospective, double-blind, placebo-controlled trial of intravenous gamma-globulin in children with chronic chest symptoms. Monogr Allergy 1988;23:168-76.
41. Vrugt B, Wilson S, van Velzen E, et al. Effects of high dose intravenous immunoglobulin in two severe corticosteroid insensitive asthmatic patients. Thorax 1997;52:662-4.
42. Dykewicz MS. Newer and alternative non-steroidal treatments for asthmatic inflammation. Allergy Asthma Proc 2001;22:11-15.
43. DeKorte CJ. Current and emerging therapies for the management of chronic inflammation in asthma. Am J Health-Syst Pharm 2003;60:1949-59.
44. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;1:CD001090.
45. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 2003;35:683-9.
46. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection: pediatrics AIDS clinic trials group. N Engl J Med 1994;331:1181-7.
47. Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003;48:209-33.
48. Broughton S, Greenough A. Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity. Expert Opin Pharmacother 2003;4:1801-8.